Form S-3 Vor Biopharma Inc For: 27 April
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Vor Biopharma Inc (VOR)
Vor Biopharma Inc stock price live, this page displays NASDAQ VOR stock exchange data. View the VOR premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Vor Biopharma Inc real time stock price chart below.
What Is the Vor Biopharma Inc Stock Price Today?
The Vor Biopharma Inc stock price today is 13.850.
What Is the Stock Symbol for Vor Biopharma Inc?
The stock symbol for Vor Biopharma Inc is "VOR."
What Stock Exchange Does Vor Biopharma Inc Trade On?
Vor Biopharma Inc is listed and trades on the NASDAQ stock exchange.
Is Vor Biopharma Inc a Good Stock to Buy?
Determining whether Vor Biopharma Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VOR quote. (ISIN: US9290332074)
What Is the Vor Biopharma Inc Stock Price Today?
The Vor Biopharma Inc stock price today is 13.850.
What Is the Stock Symbol for Vor Biopharma Inc?
The stock symbol for Vor Biopharma Inc is "VOR."
What Stock Exchange Does Vor Biopharma Inc Trade On?
Vor Biopharma Inc is listed and trades on the NASDAQ stock exchange.
Is Vor Biopharma Inc a Good Stock to Buy?
Determining whether Vor Biopharma Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VOR quote. (ISIN: US9290332074)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
13.680
14.320
52 wk Range
2.622
65.800
VOR is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
13.68014.320
52 wk Range
2.62265.800
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
VOR Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
37.500
Upside
+170.76%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings upwards for the upcoming period
- Form 13D/A VOR BIOPHARMA INC. For: 15 April
- Investing.com
- Form S-3 Vor Biopharma Inc For: 27 April
- Investing.com
- Top insider buys and sells disclosed on Wednesday
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
8 Buy
1 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 37.500
(+170.76% Upside)
Vor Biopharma Inc SWOT Analysis
AML Breakthrough | Vor Biopharma's trem-cel + Mylotarg combo shows promise in improving relapse-free survival for AML patients, with key data expected in 2025 |
Financial Runway | $91.9M cash position and $56M PIPE extend operations into Q1 2026, supporting critical clinical milestones despite negative EPS forecasts |
Market Potential | Analyst price targets range from $5 to $18, reflecting significant upside potential in the competitive oncology therapeutics landscape |
Strategic Expansion | Explore Vor's plans for a pivotal two-year controlled trial and potential applications of its technology beyond AML, diversifying its pipeline |
Earnings
Latest Release
Mar 30, 2026
EPS / Forecast
84.89 / -0.09
Revenue / Forecast
-- / --
Compare VOR to Peers and Sector
Metrics to compare | VOR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVORPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.1x | −3.4x | −0.5x | |
PEG Ratio | 0.01 | −0.09 | 0.00 | |
Price/Book | −4.6x | 3.3x | 2.6x | |
Price / LTM Sales | - | 16.3x | 3.2x | |
Upside (Analyst Target) | 179.1% | 165.6% | 47.8% | |
Fair Value Upside | Unlock | 9.3% | 6.7% | Unlock |
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren’s disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Vor Biopharma (VOR) Stock Price Today?
The Vor Biopharma stock price today is 13.850 USD.
What Stock Exchange Does Vor Biopharma Trade On?
Vor Biopharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Vor Biopharma?
The stock symbol for Vor Biopharma is "VOR."
What Is the Vor Biopharma Market Cap?
As of today, Vor Biopharma market cap is 751.820M USD.
What Is Vor Biopharma's Earnings Per Share (TTM)?
The Vor Biopharma EPS (TTM) is -70.502.
When Is the Next Vor Biopharma Earnings Date?
Vor Biopharma will release its next earnings report on Nov 07, 2025.
From a Technical Analysis Perspective, Is VOR a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Vor Biopharma Stock Split?
Vor Biopharma has split 1 times.
How Many Employees Does Vor Biopharma Have?
Vor Biopharma has 76 employees.
What is the current trading status of Vor Biopharma (VOR)?
As of May 02, 2026, Vor Biopharma (VOR) is trading at a price of 13.850 USD, with a previous close of 14.330 USD. The stock has fluctuated within a day range of 13.680 USD to 14.320 USD, while its 52-week range spans from 2.622 USD to 65.800 USD.
What Is Vor Biopharma (VOR) Price Target According to Analysts?
The average 12-month price target for Vor Biopharma is 37.500 USD, with a high estimate of 50 USD and a low estimate of 15 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +170.76% Upside potential.
What Is the VOR Premarket Price?
VOR's last pre-market stock price is 14.250 USD. The pre-market share volume is 4,020.000, and the stock has decreased by -0.080, or -0.560%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.